Latest News
“Overall, luspatercept led to durable and clinically meaningful responses beyond the achievement of the primary end point, supporting its use as the treatment of choice over ESAs in patients with transfusion-dependent lower-risk MDS–associated anemia who are ESA naive,” lead study author Amer Zeidan, MBBS, of Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and coauthors, wrote in a poster of the data.
- June 25, 2024Source: Medscape
Commenting on the research for Medscape Medical News, Maryam Lustberg, MD, associate professor, director of the Center for Breast Cancer at Smilow Cancer Hospital, and Yale Cancer Center, and chief of Breast Medical Oncology at Yale Cancer Center, in New Haven, Connecticut, said the study "builds on a body of work previously reported by others showing that neurofilament light chains as detected in the blood can be associated with early signs of neurotoxic injury."
- June 18, 2024
It is touted as the most extensive clinical-transcriptomic linkage ever accomplished. Led by Yale Urology faculty, this large collaborative study may change the way prostate cancer is predicted and treated.
- June 12, 2024
On June 11, 2024, the Yale Medical Oncology-Hematology Fellowship Graduation was held.
- June 07, 2024
The U.S. Food and Drug Administration this week approved imetelstat (known commercially as RYTELO) to treat some patients with the rare blood cancer, myelodysplastic syndromes (MDS). Amer Zeidan, MBBS, chief of hematologic malignancies at Yale Cancer Center and Associate Professor of Internal Medicine (Hematology) at the Yale School of Medicine, was one of the investigators on the IMerge phase III trial that evaluated imetelstat and the senior author of the research that published in the Lancet.
- June 06, 2024Source: WTNH News 8
The busy father of four needed a bone marrow, which is also called a stem cell transplant. “We know getting to transplant is the only way we can cure this so it’s a big landmark for patients,” said Dr. Amer Zeidan, chief of hematologic malignancies at Yale Cancer Center. The medical team at Yale Cancer Center turned to the National Marrow Donor Program, a registry of people who have gotten a cheek swab.
- June 04, 2024Source: MedScape
Dr. Cary Cross on exercise recommendations.
- June 03, 2024Source: Medscape
Cary Gross, MD, Yale professor of medicine (general internal medicine) and of epidemiology (chronic diseases), comments on a study on exercise recommendations.
- May 17, 2024Source: NewsBreak
Chemotherapies, immunotherapies, targeted therapies and hormone therapies do not improve survival rates in patients with very advanced tumors near the end of life, according to findings published Thursday in the journal JAMA Oncology .
- May 16, 2024
The findings revealed no statistically significant survival benefit for patients treated at practices that used more systemic therapy compared with those that used less.